[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100589253":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":33,"centralContacts":37,"locations":46,"responsibleParty":153,"collaborators":25,"id":155,"slug":25,"hasResults":156,"nctId":157,"briefTitle":158,"officialTitle":159,"acronym":25,"eligibilityCriteria":160,"healthyVolunteers":156,"sex":161,"minAge":162,"maxAge":25,"enrollmentInfo":163,"targetDuration":25,"studyType":166,"phases":167,"briefSummary":169,"conditions":170,"keywords":175,"overallStatus":49,"whyStopped":25,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":185,"completionDateStruct":187,"leadSponsor":189,"locationsCount":190},{"fullName":5,"class":6},"Exelixis","INDUSTRY",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Dose Escalation Phase","EXPERIMENTAL","Participants with recurrent advanced or metastatic solid tumors will receive escalating dose levels doses of XB628 as a single agent and in combination with zanzalintinib.",[13,14],"Biological: XB628","Drug: Zanzalintinib",{"label":16,"type":10,"description":17,"interventionNames":18},"Dose Expansion","Participants with recurrent advanced or metastatic solid tumors will receive XB628 as a single agent and in combination with zanzalintinib.",[13,14],[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"BIOLOGICAL","XB628","Intravenous infusion(s)",[9,16],null,{"type":27,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"DRUG","Zanzalintinib","Oral tablet(s)",[9,16],[32],"XL092",[34],{"name":35,"affiliation":5,"role":36},"Medical Director","STUDY_DIRECTOR",[38,43],{"name":39,"role":40,"phone":41,"phoneExt":25,"email":42},"Exelixis Clinical Trials","CONTACT","1-888-EXELIXIS (888-393-5494)","druginfo@exelixis.com",{"name":44,"role":40,"phone":45,"phoneExt":25,"email":25},"Backup or International","650-837-7400",[47,60,70,80,90,95,105,114,124,134,144],{"facility":48,"status":49,"city":50,"state":51,"zip":52,"country":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":25},"Exelixis Clinical Site #5","RECRUITING","San Francisco","California","94158","United States",{"type":55,"coordinates":56},"Point",[57,58],-122.41942,37.77493,{"lat":58,"lon":57},{"facility":61,"status":49,"city":62,"state":63,"zip":64,"country":53,"cosmosGeoPoint":65,"geoPoint":69,"contacts":25},"Exelixis Clinical Site #4","New Haven","Connecticut","06520",{"type":55,"coordinates":66},[67,68],-72.92816,41.30815,{"lat":68,"lon":67},{"facility":71,"status":49,"city":72,"state":73,"zip":74,"country":53,"cosmosGeoPoint":75,"geoPoint":79,"contacts":25},"Exelixis Clinical Site #8","Tampa","Florida","33612",{"type":55,"coordinates":76},[77,78],-82.45843,27.94752,{"lat":78,"lon":77},{"facility":81,"status":49,"city":82,"state":83,"zip":84,"country":53,"cosmosGeoPoint":85,"geoPoint":89,"contacts":25},"Exelixis Clinical Site #10","Boston","Massachusetts","02114",{"type":55,"coordinates":86},[87,88],-71.05977,42.35843,{"lat":88,"lon":87},{"facility":91,"status":49,"city":82,"state":83,"zip":84,"country":53,"cosmosGeoPoint":92,"geoPoint":94,"contacts":25},"Exelixis Clinical Site #11",{"type":55,"coordinates":93},[87,88],{"lat":88,"lon":87},{"facility":96,"status":49,"city":97,"state":98,"zip":99,"country":53,"cosmosGeoPoint":100,"geoPoint":104,"contacts":25},"Exelixis Clinical Site #6","St Louis","Missouri","63108",{"type":55,"coordinates":101},[102,103],-90.19789,38.62727,{"lat":103,"lon":102},{"facility":106,"status":49,"city":107,"state":107,"zip":108,"country":53,"cosmosGeoPoint":109,"geoPoint":113,"contacts":25},"Exelixis Clinical Site #7","New York","10029",{"type":55,"coordinates":110},[111,112],-74.00597,40.71427,{"lat":112,"lon":111},{"facility":115,"status":49,"city":116,"state":117,"zip":118,"country":53,"cosmosGeoPoint":119,"geoPoint":123,"contacts":25},"Exelixis Clinical Site #1","Hickory","North Carolina","28602",{"type":55,"coordinates":120},[121,122],-81.3412,35.73319,{"lat":122,"lon":121},{"facility":125,"status":49,"city":126,"state":127,"zip":128,"country":53,"cosmosGeoPoint":129,"geoPoint":133,"contacts":25},"Exelixis Clinical Site #3","Nashville","Tennessee","37203",{"type":55,"coordinates":130},[131,132],-86.78444,36.16589,{"lat":132,"lon":131},{"facility":135,"status":49,"city":136,"state":137,"zip":138,"country":53,"cosmosGeoPoint":139,"geoPoint":143,"contacts":25},"Exelixis Clinical Site #9","Houston","Texas","77030",{"type":55,"coordinates":140},[141,142],-95.36327,29.76328,{"lat":142,"lon":141},{"facility":145,"status":49,"city":146,"state":137,"zip":147,"country":53,"cosmosGeoPoint":148,"geoPoint":152,"contacts":25},"Exelixis Clinical Site #2","San Antonio","78229",{"type":55,"coordinates":149},[150,151],-98.49363,29.42412,{"lat":151,"lon":150},{"type":154,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100589253",false,"NCT06952010","A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid Tumors","A Phase 1 Dose Escalation and Expansion Study of XB628 as a Single Agent and in Combination With Zanzalintinib in Participants With Advanced or Metastatic Solid Tumors","Key Inclusion Criteria:\n\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.\n* Minimum life expectancy of ≥ 12 weeks.\n* Have a recurrent advanced or metastatic solid tumor that is histologically or cytologically confirmed.\n* Adequate organ and marrow function.\n* Not amenable to curative treatment with surgery or radiation.\n* Received at least 1 line of prior systemic anticancer therapy in the recurrent or metastatic setting.\n* Acceptable alternative therapy was received, refused, intolerable, or no longer effective.\n* Capable of understanding and complying with the protocol requirements and provide signed informed consent according to the protocol and local requirements.\n\nKey Exclusion Criteria\n\n* Primary brain tumors or known active brain metastases.\n* Major surgery (eg, gastrointestinal surgery, removal or biopsy of brain metastasis) within 4 weeks before the first dose of study treatment.\n* Received radiation therapy within 1 week before the first dose of study treatment or clinically relevant ongoing complications from prior radiation therapy.\n* Received prior therapy targeting NK cells (eg, monalizumab).\n* A woman of childbearing potential has a positive serum pregnancy test within 7 days prior to study treatment.\n\nNote: Other protocol defined Inclusion\u002FExclusion criteria may apply.","ALL","18 Years",{"count":164,"type":165},303,"ESTIMATED","INTERVENTIONAL",[168],"PHASE1","This study consists of a Dose-Escalation stage and a Dose Expansion stage. The primary purpose of the dose escalation stage is to determine the maximum tolerated dose (MTD) and\u002For recommended dosage(s) for expansion (RDE\\[s\\]); and the dose expansion stage is to evaluate the preliminary antitumor activity of XB628 as a single agent and in combination with zanzalintinib.",[171,172,173,174],"Solid Tumor","Advanced Solid Tumor","Metastatic Solid Tumor","Immune Sensitive Tumor",[22,176,177,178,179,180,28],"Solid tumor","Advanced solid tumor","Metastatic solid tumor","Immune sensitive tumor","PD-L1","2026-06-19",{"date":183,"type":184},"2026-06-24","ACTUAL",{"date":186,"type":184},"2025-05-01",{"date":188,"type":165},"2027-11-30",{"name":5,"class":6},11]